Published in Clin Neurosci Res on January 01, 2005
Electrophysiological effects of anandamide on rat myocardium. Br J Pharmacol (2009) 0.82
Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) (2012) 0.80
Anandamide reduces intracellular Ca2+ concentration through suppression of Na+/Ca2+ exchanger current in rat cardiac myocytes. PLoS One (2013) 0.78
The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. Bonekey Rep (2012) 0.75
Cannabinoids Occlude the HIV-1 Tat-Induced Decrease in GABAergic Neurotransmission in Prefrontal Cortex Slices. J Neuroimmune Pharmacol (2016) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 4.27
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science (1997) 3.77
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry (2004) 3.26
Cannabinoids: potential anticancer agents. Nat Rev Cancer (2003) 2.87
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med (2000) 2.85
Cannabis and the brain. Brain (2003) 2.63
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience (1997) 2.56
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction (1999) 2.51
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science (1997) 2.50
Cannabinoid receptors and pain. Prog Neurobiol (2001) 2.48
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 2.48
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1997) 2.31
The effects of cannabinoids on the brain. Prog Neurobiol (1999) 2.29
Cannabinoid pharmacology. Pharmacol Rev (1986) 2.15
Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 2.15
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler (2004) 2.15
Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry (2001) 2.13
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci (1998) 2.12
60- and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: cognitive and language assessment. J Dev Behav Pediatr (1992) 2.07
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology (2001) 2.03
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc (2003) 1.91
Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer (2002) 1.87
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther (2004) 1.83
Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med (1980) 1.78
Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 1.77
Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 1.76
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology (2004) 1.73
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience (1999) 1.73
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res (1991) 1.67
The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon (2004) 1.67
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol (1998) 1.65
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol (2000) 1.61
Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) (2001) 1.57
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience (2000) 1.56
Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci (2000) 1.55
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci (2002) 1.52
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage (1995) 1.51
The brain's own marijuana. Sci Am (2004) 1.50
The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther (1975) 1.49
Therapeutic potential of cannabinoids in CNS disease. CNS Drugs (2003) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem (2003) 1.44
Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse (1999) 1.44
Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol (1975) 1.42
Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci (1998) 1.39
Cannabinoids in clinical practice. Drugs (2000) 1.35
Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol (2004) 1.33
Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol (2002) 1.30
Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol (2004) 1.29
Conduct problems and early cannabis initiation: a longitudinal study of gender differences. Addiction (2001) 1.27
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse (1987) 1.26
Cannabinoid addiction: behavioral models and neural correlates. J Neurosci (2002) 1.24
Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol (1998) 1.24
Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol (1988) 1.23
Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia (2001) 1.22
Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther (2002) 1.20
Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage (1997) 1.15
Antineoplastic activity of cannabinoids. J Natl Cancer Inst (1975) 1.14
Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs (2003) 1.13
Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem (2001) 1.13
De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J (2002) 1.13
Cannabinoids and multiple sclerosis. Pharmacol Ther (2002) 1.12
Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med (2003) 1.11
Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology (2005) 1.10
Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav (2001) 1.10
Reading and language in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol (1997) 1.09
Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med (1980) 1.08
Cannabinoids and glaucoma. Br J Ophthalmol (2004) 1.07
Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc (2004) 1.06
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol (1989) 1.06
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology (2005) 1.06
Cannabinoids in the treatment of glaucoma. Pharmacol Ther (2002) 1.05
Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology (Berl) (1999) 1.05
Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol (1998) 1.04
Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol (2004) 1.03
CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol (2000) 1.03
Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther (1977) 1.02
Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther (2000) 1.02
SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol (1999) 1.01
Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol (2006) 1.09
Awakening is not a metaphor: the effects of Buddhist meditation practices on basic wakefulness. Ann N Y Acad Sci (2013) 0.81
The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry (2010) 0.79